Skip to Content

Join the 'Von Willebrand Factor' group to help and get support from people like you.

Von Willebrand Factor News

FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD

Posted 10 Dec 2015 by Drugs.com

December 8, 2015 – The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD. VWD is the most common inherited bleeding disorder, affecting approximately 1 percent of the U.S. population. Men and women are equally affected by VWD, which is caused by a deficiency or defect in von Willebrand factor, a protein that is critical for normal blood clotting. Patients with VWD can develop severe bleeding from the nose, gums, and intestines, as well as into muscles and joints. Women with VWD may have heavy menstrual periods lasting longer than average and may experience excessive ... Read more

Related support groups: von Willebrand's Disease, Von Willebrand Factor, Vonvendi, Von Willebrand Factor (recombinant)

Ask a Question

Further Information

Related Condition Support Groups

von Willebrand's Disease

Related Drug Support Groups

Wilfactin, Vonvendi

Von Willebrand Factor Patient Information at Drugs.com